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Global burden of Shigella infections: implications
for vaccine development and implementation of
control strategies
K.L. Kotloff,1 J.P. Winickoff,2 B. Ivanoff,3 J.D. Clemens,4 D.L. Swerdlow,5
P. J. Sansonetti,6 G.K. Adak,7 & M.M. Levine8
Few studies provide data on the global morbidity and mortality caused by infection with Shigella spp.; such estimates
are needed, however, to plan strategies of prevention and treatment. Here we report the results of a review of the
literature published between 1966 and 1997 on Shigella infection. The data obtained permit calculation of the number
of cases of Shigella infection and the associated mortality occurring worldwide each year, by age, and (as a proxy for
disease severity) by clinical category, i.e. mild cases remaining at home, moderate cases requiring outpatient care, and
severe cases demanding hospitalization. A sensitivity analysis was performed to estimate the high and low range of
morbid and fatal cases in each category. Finally, the frequency distribution of Shigella infection, by serogroup and
serotype and by region of the world, was determined.
The annual number of Shigella episodes throughout the world was estimated to be 164.7 million, of which
163.2 million were in developing countries (with 1.1 million deaths) and 1.5 million in industrialized countries. A total
of 69% of all episodes and 61% of all deaths attributable to shigellosis involved children under 5 years of age. The
median percentages of isolates of S. flexneri, S. sonnei, S. boydii, and S. dysenteriae were, respectively, 60%, 15%,
6%, and 6% (30% of S. dysenteriae cases were type 1) in developing countries; and 16%, 77%, 2%, and 1% in
industrialized countries. In developing countries, the predominant serotype of S. flexneri is 2a, followed by 1b, 3a, 4a,
and 6. In industrialized countries, most isolates are S. flexneri 2a or other unspecified type 2 strains.
Shigellosis, which continues to have an important global impact, cannot be adequately controlled with the
existing prevention and treatment measures. Innovative strategies, including development of vaccines against the
most common serotypes, could provide substantial benefits.
Voir page xx le re´sume´ en franc¸ais. En la pagina xx figura un resumen en espan˜ol.
Introduction
A convergence of events and opportunities makes
this a propitious moment to estimate the magnitude
of the global burden of disease and death caused by
Shigella. Several recent trends underscore the limita-
tions of modern medical and public health efforts in
controlling this global threat, the consequences of
which are most devastating in the developing world.
Since the 1970s, the vigorous use of oral rehydration
therapy in developing countries has contributed
significantly to reductions in mortality from diar-
rhoeal dehydration (1–4). In contrast, this interven-
tion provides little benefit to patients with dysentery
caused by invasive bacterial enteropathogens such as
Shigella. As a result, the relative importance of
dysentery as a clinical problem in developing
countries has increased (5). At a diarrhoeal disease
centre in Bangladesh, between 1975 and 1985, deaths
attributed to acute or chronic dysentery among 1–4-
year-old children outnumbered the deaths attributed
to acute or chronic watery diarrhoea by a factor
ranging from 2.1 to 7.8 (6).
Over the last 50 years, Shigella has demonstrated
extraordinary prowess in acquiring plasmid-encoded
resistance to the antimicrobial drugs that previously
constituted first-line therapy. Sulfonamides, tetra-
cycline, ampicillin and trimethoprim–sulfamethox-
azole initially appeared as highly efficacious drugs,
only to become impotent in the face of emerging
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resistance (7). In the 1990s, few reliable options exist
to treat multiresistant Shigella infections, particularly
in developing countries where cost and practicality
are paramount considerations.
Since the late 1960s, pandemic waves of Shiga
(S. dysenteriae type 1) dysentery have appeared in
Central America, south and south-east Asia and sub-
Saharan Africa, often affecting populations in areas of
political upheaval and natural disaster (8–10). When
pandemic S. dysenteriae type 1 strains invade these
vulnerable populations, the attack rates are high and
dysentery often becomes a leading cause of death (10).
Shigella infections also occur in industrialized
countries (11, 12). Groups that exhibit suboptimal
levels of hygiene, such as toddlers and preschool-age
children in day-care centres (13) or persons residing
in custodial institutions (14), can experience out-
breaks of shigellosis. In some urban areas, endemic
transmission is sustained. Shigella spp. are common
etiological agents of diarrhoea among travellers to
less developed regions of the world, and tend to
produce a more disabling illness than enterotoxigenic
Escherichia coli (15), the leading cause of travellers’
diarrhoea syndrome.
The intersection of Shigella infections and the
human immunodeficiency virus (HIV) epidemic has
had serious consequences. Both chronic diarrhoea
and dysentery are common among persons infected
with HIV (16, 17); in studies of chronic diarrhoea and
dysentery in developing regions, Shigella has some-
times been the most common pathogen identified
(17, 18). In industrialized countries, Shigella spp. are
often identified in homosexual men with colitis or
proctocolitis (19, 20). Although it is not known
whether the risk of acquiring shigellosis is enhanced
by concomitant HIV infection (21), it appears that
HIV-associated immunodeficiency leads to more
severe clinical manifestations of Shigella infection.
Patients with HIV infection may develop persistent
or recurrent intestinal Shigella infections, even in the
presence of adequate antimicrobial therapy. They
also face an increased risk of Shigella bacteraemia,
which can be recurrent, severe or even fatal (22–25).
Despite the continuing challenge posed by
Shigella, there is room for optimism as advances in
biotechnology have enabled the development of a
new generation of candidate vaccines that shows
great promise for the prevention of Shigella disease
(26–28). The state of progress in the development
and testing of the new Shigella vaccines was reviewed
at a meeting convened by WHO (29). As with any
new vaccine, assessments of cost-effectiveness and
other economic analyses help guide both develop-
ment and implementation. A prerequisite to such
economic analyses is a reliable estimate of Shigella
disease burden, including information on the relative
occurrence of the various serogroups and serotypes
in different geographical areas (30). In view of the
background summarized above, we have quantified
the global burden of Shigella infections in both
developing and industrialized countries.
Materials and methods
The initial studies selected for this review were
identified by a computer search of the multilingual
scientific literature published between 1966 and
1997. A set of 9240 articles, derived using the
keywords Shigella, dysentery, bacillary, and shigellosis,
was linked with a set of 902 934 articles obtained
using the following keywords that dealt with disease
burden: incidence, prevalence, public health, death
rate, mortality, surveillance, burden, suffering, dis-
tribution, area, location, country, and permutations
of the root words: epidemiol-, monitor-, geograph-.
The resulting cross-linked set contained 1530 articles
which were culled to select 305 articles relevant to the
stated goal of the search (available upon request).
Additional (mainly pre-1966) references were found
from citations listed in these 305 articles and from the
archives of the authors and experts in the field.
An algorithm was created to estimate the
number of cases of Shigella infection that occur
worldwide each year. In a preliminary step, the
world’s population was divided into ten strata based
on age (0–11 months, 1–4 years, 5–14 years, 15–59
years, and >60 years); countries were designated as
developing or industrialized according to United
Nations criteria (31). Published rates of diarrhoeal
incidence for each of the ten strata were used to
estimate the diarrhoeal disease burden. The propor-
tion of diarrhoeal episodes attributable to Shigella
depends on the severity of the patient’s illness. We
expected that this correlation would increase as the
percentage of Shigella infections increases as sampling
progresses from cases of diarrhoea detected by
household surveillance to those found among out-
patients in treatment centres to those that were
admitted to hospital with diarrhoeal illness (32).
Accordingly, the total diarrhoeal disease burden was
subdivided into three settings: estimates of mild cases
remaining at home; more severe cases requiring
clinical care at a treatment centre but not needing
hospitalization; and cases demanding hospitalization.
The proportion of diarrhoea episodes in each
stratum that can be attributed to shigellosis was
estimated by analysing studies that met the following
criteria: the percentage of diarrhoea cases that were
microbiologically confirmed as due to Shigella using
conventional bacteriological culture methods was
reported for the specified age group (33); the sample
included at least 100 cases of diarrhoea, i.e. there was
a >99% probability of detecting at least one case if the
true prevalence was 5%; surveillance was conducted
for at least one year; and for household studies, there
was at least biweekly surveillance for diarrhoea. When
multiple studies were conducted in one country
during overlapping time spans and in similar settings,
a median value for shigellosis cases was derived. An
overall median percent shigellosis was then calculated
for each stratum and multiplied by the total number
of diarrhoeal cases in the stratum to derive the
number of Shigella cases in each stratum. These
numbers of Shigella cases were summed to give an
Research
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overall burden of Shigella morbidity. Published case-
fatality rates for persons hospitalized with Shigella
infection were used to calculate age-specific rates of
Shigella-associated mortality.
To estimate the burden of Shigella infection by
serogroup and serotype, we analysed studies that met
the following criteria: 1) systematic microbiological
surveillance had been performed for at least one year,
using recognized laboratory techniques (33); 2) with
the exception of one community cohort study in
Guatemala (34), the clinical venue was either a
treatment setting or an inpatient ward of a hospital,
thereby capturing serotypes associated with a more
severe spectrum of clinical illness; and 3) data were
collected after 1979. Countries were grouped by
region according to published criteria (31) and a
median frequency distribution by region was calcu-
lated.
Results
Endemic disease among under-5-year-olds
in developing countries
Population statistics. Of the total world population
of ca. 5700 million inhabitants in 1995, nearly
4600 million people were estimated to reside in non-
industrialized countries (35), including 125 million
infants aged 0–11 months and 450 million children
aged 1–4 years.
Diarrhoeal incidence. The estimates of Bern et
al. (36) were used to gauge the number of episodes of
diarrhoea per year among under-1-year-old infants
and in children aged 1–4 years. These estimates are
based on a review of 22 longitudinal community
studies of stable populations in 12 developing
countries in Asia, Latin America and Africa where
active surveillance for diarrhoea was conducted
between 1981 and 1987 using at least biweekly home
monitoring for a minimum of 1 year. The median
incidences were 3.9 episodes per child per year for
0–11-month-olds and 2.1 episodes per child per year
for children aged 1–4 years.
Total number of diarrhoeal episodes. By
multiplying the population of children by the
incidence of diarrhoea in each age group, we
calculated the total number of diarrhoeal episodes
to be 487. 5 million for 0–11-month-old infants and
945 million for children aged 1–4 years (Table 1).
Number of diarrhoeal episodes in the three
study settings. Data collected in the mid-1980s in a
poor peri-urban community in Santiago, Chile,
revealed that among 0–11-month-olds, 88.2% of
episodes of diarrhoea were mild cases that did not
seek health care but were detected by active house-
hold surveillance, 10.3% were outpatients at an
ambulatory treatment centre, and 1.5% required
hospital admission (32 and R. Lagos, unpublished
data, 1989). Among 1–4-year-olds, 91.9% of epi-
sodes were domiciliary, 7.9% went to treatment
centres, and 0.2% were admitted to hospitals. These
estimates were confirmed in another part of Chile
using data from 1995 and 1996 (R. Lagos, P. Abrego,
M.M. Levine, unpublished data, 1996). Since we did
not have similar data available from other areas in
nonindustrialized countries, the Chilean data were
extrapolated to estimate the overall number of
diarrhoea cases in each age group who stayed at
home, were seen at a treatment centre, or were
admitted to hospital (Table 1).
Percentage of diarrhoea due to Shigella in the
three study settings. Studies conducted in a devel-
oping country that met the inclusion criteria were
analysed to determine the percentage of diarrhoea
cases due to Shigella among children aged 0–11
months and 1–4 years.
. 0–11-Month-old infants. As shown in Table 2, the
median frequency of Shigella isolation from
diarrhoea cases in this age group was 3.2% (range,
2.2–5.3%) for those treated at home (results of six
studies: 32, 37–41), 6.3% (range, 1.6–30.0%) for
those in treatment centres (eight studies: 32, 42–
47), and 6.5% (range, 3.6–11.0%) for those treated
in hospital (four studies: 32, 48–50).
. 1–4-Year-old children. As shown in Table 3, the
median percentage of diarrhoeal episodes from
which Shigella was cultured was 9.1% (range,
5.5–18.7%) in household cases (four studies: 32,
40, 41, 51), 22.0% (range, 13.0–39.0%) for those
in treatment centres (six studies: 32, 42–44, 46),
and 16.5% (range, 8.0–32.0%) for those treated in
hospital (four studies: 32, 48–50).
Burden of shigellosis in under-5-year-olds in
the three study settings. The total number of cases of
diarrhoea attributable to Shigella in each of the three
settings was calculated for the 0–11-month and
1–4-year age groups by multiplying the percentage of
episodes from which Shigella was identified by the
Table 1. Estimating the annual number of episodes of diarrhoea
among 0–4-year-old children living in developing countries, by age
group, in each of three settings
Age group
0–11 months 1–4 years Total
(0–4 years)
Total population 125 000 000 450 000 000 575 000 000
No. of diarrhoeal episodes
per child per year a 3.9 2.1 NAb
Total: all diarrhoeal episodes 487 500 000 945 000 000 1 432 500 000
No. of episodes at home 429 975 000 868 455 000 1298 430 000
(91.9) (88.2)c
No. of episodes in outpatients 50 212 500 74 655 000 124 867 500
(10.3)b (7.9)
No. of cases hospitalized 7 312 500 1 890 000 9 202 500
(1.5)b (0.2)
a From ref. 36.
b NA: not applicable.
c Figures in parentheses are percentages of total diarrhoeal episodes (from ref. 32).
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number of diarrhoea cases seen in each setting, as
summarized in Table 4. In this manner, it was
estimated that a total of 113 163 260 episodes of
shigellosis occurred each year among under-5-year-
olds in the developing world.
Endemic disease among older children and
adults living in developing countries
Population statistics. Three age strata were used in
estimating the Shigella disease burden among older
children and adults: 5–14 years (school-age children),
15–59 years (adults), and 560 years (elderly). The
population of these age groups in developing
countries is 1 010 985 000, 2 646 608 000 and
329 450 000, respectively, i.e. a total of 3 987 043 000
(35).
Incidence and burden of diarrhoea. Only a
single household-based epidemiological study of
adults could be identified which fulfilled our criteria;
even this study, which was conducted in southern
China, was suboptimal in that surveillance was
conducted only once per month. In this Chinese
study, for the age groups 5–14 years, 15–59 years and
560 years, the average incidence of diarrhoea was
0.65, 0.50, and 0.69 episodes per person per year,
Table 2. Proportion of diarrhoeal episodes in which Shigella was detected among infants aged 0–11 months in three
surveillance settings
Domicile Outpatient treatment centre Hospital
0 00 0 0 0




Country Years Setting episodes Country Years Setting episodes Country Years Setting episodes
Chile( ref. 32) 1986–89 Urban 8/171 (4.7)a Chile (ref. 32) 1986–89 Urban 30/605 (5.0) Chile (ref. 32) 1986–89 Urban 17/215 (8.0)
Mexico (ref. 37) 1985–87 Rural 7/314 (2.2) Nigeria (ref. 43) 1984–85 Rural 43/391 (11.0) India ( ref. 48) 1985–88 Urban 22/210 (11.0)
Peru (ref. 38) 1982–84 Urban 19/825 (2.3) Bangladesh (ref. 46) 1975–84 Rural 49/162 (30.0) Philippines (ref. 49) 1983–84 Urban 63/1247 (5.0)
Mexico (ref. 39) 1982–83 Rural 9/170 (5.3) Bangladesh (ref. 42) 1983–84 Rural 14/240 (6.0) Islamic Republic 1986–87 Urban 19/527 (3.6)
Thailand (ref. 40) 1988–89 Urban 4/164 (2.4) Bangladesh (ref. 44) 1979–80 Urban 57/876 (6.5) of Iran (ref.50)
Egypt (ref. 41) 1981–83 Rural 8/207 (3.9) Brazil (ref. 45) 1985–86 Urban 25/500 (5.0)
Somalia (ref. 47) 1983–84 Urban 12/745 (1.6)
China, India,
Mexico, Pakistan
(ref. 98) 1982–85 Urban 137/1809 (7.6)
Median % 3.2 6.3 6.5
a Figures in parentheses are percentages.
Table 3. Proportion of diarrhoeal episodes in which Shigella was detected among children aged 1–4 years in three
surveillance settings
Domicile Outpatient treatment centre Hospital
0 00 0 0 0




Country Years Setting episodes Country Years Setting episodes Country Years Setting episodes
Chile (ref. 32) 1986–89 Urban 106/966 (11.0)a Chile (ref. 32) 1986–89 Urban 138/1050 (13.0) Chile(ref. 32) 1986-89 Urban 21/65 (32.0)
Bangladesh (ref.51) 1978–79 Rural 68/364 (18.7) Nigeria (ref. 43) 1984–85 Rural 121/826 (15.0) Philippines (ref. 49) 1983–84 Urban 110/1152 (10.0)
Thailand (ref. 40) 1988–89 Urban 13/181 (7.2) Bangladesh (ref. 46)b 1975–84 Rural 285/740 (39.0) India (ref. 48) 1985–88 Urban 170/740 (23.0)
Egypt (ref. 41) 1981–83 Rural 35/636 (5.5) Bangladesh (ref. 42) 1983–84 Rural 73/523 (14.0) Islamic Republic 1986–87 Urban 13/170 (8.0)
Bangladesh (ref. 44)b 1979–80 Urban 379/1310 (29.0) of Iran (ref. 50)
China, India, 1982–85 Urban 230/1004 (29.0)
Mexico, Pakistan
(ref. 98)b
Median % 9.1 22.0 16.5
a Figures in parentheses are percentages.
b Children evaluated were 1–3 years of age.
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respectively (52). This suggests that the lower
estimate of diarrhoeal incidence among over-5-
year-olds is roughly 0.5 episodes per person per year,
i.e. 50% of persons in this age group experience
diarrhoea each year. We applied these rates to
estimate the age-specific annual number of diarrhoeal
episodes occurring in older children and adults in
developing countries (Table 5).
Percentage of diarrhoeal illness reaching
medical attention. Only one study was found that
could be used to estimate the incidence of diarrhoea
in adults that was of sufficient severity to prompt
individuals to seek medical care. This study measured
the number of cases of diarrhoea seen at health
centres that serve 90% of people living in a
community of 140 000 residents in a lower socio-
economic suburb of Lima, Peru, and reported an





Age group Domicile Outpatient Inpatient diarrhoea
0–11 months
Annual number of diarrhoea episodes 429 975 000 50 212 500 7 312 500
% episodes with Shigella spp. 3.2 6.3 6.5
Total Shigella episodes 13 759 200 3 163 390 475 315 17 397 905
1–4 years
Annual number of diarrhoea episodes 868 455 000 74 655 000 1 890 000
% episodes infected with Shigella spp. 9.1 22.0 16.5
Total Shigella episodes 79 029 405 16 424 100 311 850 95 765 355
Total Shigella episodes, 0–4 years 92 788 605 19 587 490 787 165 113 163 260
Table 5. Annual numbers of diarrhoea episodes and of Shigella episodes among older children and
adults living in developing countries
Age group
5–14 years 15–59 years 560 years Total
Population 1 010 985 000 2 646 608 000 329 450 000 3 987 043 000
No. of diarrhoeal episodes per person 0.65 0.50 0.69 NAb
per yeara
Total number of diarrhoeal episodes 657 140 250 1 323 304 000 227 320 500 2 207 764 750
Annual number of diarrhoeal episodes:
Reaching a treatment facilityc 13 142 805 26 466 080 4 546 410 44 155 295
Remaining in domicile 643 997 445 1 296 837 920 222 774 090 2 163 609 455
Estimated % of diarrhoeal episodes attributed
to Shigella:
Reaching a treatment facilityd 13.5 15.6 18.5 NA
Remaining in domicilee 2.0 2.0 2.0 NA
Annual number of Shigella diarrhoea episodes:
Reaching a treatment facility 1 774 280 4 128 710 841 085 6 744 075
Remaining in domicile 12 879 950 25 936 760 4 455 480 43 272 190
Total 14 654 230 30 065 470 5 296 565 50 016 265
a Ref. 52.
b NA: not applicable.
c This calculation assumes that approximately 2% of diarrhoeal episodes reach a treatment facility, and is based on the observation that at
least 50% of persons in this age group experience diarrhoea each year (ref. 52) and 1.2% seek medical care (ref. 53), i.e. approximately 0.012/0.50,
or 2% of diarrhoeal episodes in developing countries require medical attention each year.
d From Table 6.
e The percentage is based on estimates from reference 54.
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annual rate of 11.8 episodes per 1000 population, i.e.
1.2% (53). Limitations of the study were that it lasted
only 6 months (January to June), did not stratify by
age after 15 years, and did not differentiate outpatient
visits from hospitalizations. Thus, an overall estimate,
without stratification for age or treatment setting, was
made for the proportion of patients aged >5 years
who sought medical care for their diarrhoeal illness,
as follows: if 50% of persons in this age group
experience diarrhoea each year (vide supra), and 1.2%
seek medical care (53), approximately 0.012/0.50
(2%) of diarrhoeal episodes among school-aged
children and adults living in developing countries
require medical attention each year (Table 5).
Percentage of diarrhoea that is attributable to
Shigella. Table 6 summarizes the studies that report
the percentage of diarrhoeal episodes associated with
Shigella isolation in all types of treatment centres or
hospitals for patients aged 55 years. The median
percentages for the age groups 5–14, 15–59, and
560 years were estimated to be 13.5%, 15.6%, and
18.5%, respectively. No studies provide data to
indicate what proportion of the remaining cases of
diarrhoea that are mild (i.e. do not result in health care
visits) might be attributable to Shigella, although some
experts have estimated 8% (54). To maintain
conservative estimates, we selected 2% as the value
to use in further calculations (Table 5).
Total burden of shigellosis among older
children and adults living in developing countries.
The assumptions stated above permit a calculation of
the total annual Shigella burden, i.e. cases remaining at
home and those receiving medical attention among
children aged 55 years and adults living in
developing countries. The burden was calculated by
multiplying the number of patients with diarrhoea in
each age stratum and clinical venue by the median
proportion of episodes in each age stratum that is
estimated to be caused by Shigella. Thus, the estimated
annual number of cases of shigellosis among persons
aged 5–14, 15–59, and 560 years is 14 654 230,
30 065 470 and 5 296 565, respectively, i.e. a total of
50 016 265 (Table 5).
Total burden of shigellosis among persons
living in developing countries. The estimated disease
burden from shigellosis among adults and older
children living in developing countries is roughly
50.0 million cases per year (Table 5). This compares
with ca. 113.2 million cases for the age group <5 years
(Table 4), and results in an estimated annual disease
burden for all age groups living in developing
countries of 163.2 million persons.
Cases of shigellosis
in industrialized countries
The Shigella burden in industrialized countries was
calculated using national surveillance data because
there is a paucity of prospective longitudinal studies.
Surveillance data are presented below from Australia,
France, England and Wales, Israel, and USA. To
obtain a more accurate estimate of disease incidence,
a correction factor based on the rate of case
ascertainment (completeness of reporting) was
applied to the reported incidences, as described
below.
Shigella in Australia. Shigella isolations are
reported to the Australian National Notifiable
Diseases Surveillance System from all States and
Territories, except New South Wales, where it was
only reportable as a foodborne disease in two or more
related cases or as gastroenteritis in an institutional
Table 6. Percentage of diarrhoeal episodes that were evaluated in treatment centres and hospitals in
which Shigella was isolated among patients aged 55 years living in developing countries
No. of episodes in which Shigella was isolated in each
assigned age stratuma (%)
Country Year Setting 5–14 years 15–59 years 560 years
Saudi Arabia (ref. 99) 1987–89 Rural NRb 18/71 (25.3) NR
Bangladesh (ref. 46) 1975–84 Rural 275/588 (46.8) 284/771 (36.8) 78/227 (34.4)
Bangladesh (ref. 42) 1983–84 Rural 67/537 (12.5) 60/786 (7.6) 32/246 (13.0)
Bangladesh (ref.44) 1979–80 Urban 57/438 (13.0) 107/869 (12.3) 13/57 (22.8)
Thailand (ref. 100) 1982–83 Rural 5/25 (20.0) 4/86 (4.7) 9/66 (13.6)
Thailand (ref. 101) 1980–81 Urban NR 181/660 (27.4) NR
India (ref.102) 1976–85 Urban 87/1919 (4.5) 136/4050 (3.4) 86/983 (8.7)
Philippines (ref.103) 1982–88 Urban 24/110 (21.8) 91/306 (29.7) 31/93 (33.3)
Philippines (ref. 49) 1983–84 Urban 21/346 (6.1) 53/674 (7.9) NR
Median % 14.0c Median % 18.8c
Median % 13.5 15.6 18.5
a When data were not stratified into these age categories, the results were assigned to the most comparable group.
b NR: not reported.
c A median was derived for the Philippines since both studies involved similar populations during overlapping times.
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setting. The overall rate in 1996 was 5.6 per
100 000 population.
Shigella in France. During the most recent
6-year period for which data are available (1992–97),
an average of 962 cases of Shigella infection were
reported to the Centre National de Re´fe´rence des Salmonella
et Shigella, Pasteur Institute, Paris. Applying the United
Nations estimate of France’s population in 1995 yields
a rate of 1.8 cases per 100 000 population.
Shigella infection in England and Wales.
The age-specific incidence of shigellosis in England
and Wales has been estimated for 1996, based on
cases reported to the Public Health Laboratory
Service. The incidence of Shigella infection was
3.3 cases per 100 000 population (Table 7).
Shigella infection in Israel. During the most
recent 5-year period for which data are available
(1991–95), the mean incidence of laboratory-
confirmed Shigella infection in the civilian population
of Israel that was reported to regional health
authorities was 130 cases per 100 000 population
per year (56). Age-specific incidences for the Jewish
and non-Jewish populations are shown in Table 7.
Shigella infection in the USA. A total of
59 527 cases of laboratory-confirmed Shigella infec-
tion were reported to the US National Shigella
Surveillance System (PHLIS) over the 5-year period
1990–94 (average 11 900 per year) (55). Over the
same period, an additional 27 899 cases were reported
from states not participating in the PHLIS system,
yielding a total number of 87 426 Shigella cases for the
USA, i.e. an average of 17 500 cases per year (55).
This corresponds to 6.5 cases per 100 000 population
(Table 8). The age-specific incidences of shigellosis,
calculated from the reported age data of a single year
(1 October 1994 to 12 September 1995), are shown in
Table 7 (55).
Age-specific and total burden of Shigella in
industrialized countries. As shown in Table 7, the
incidence of shigellosis reported in Australia, Eng-
land and Wales, France, and the USA is similar,
ranging from 1.8 to 6.5 cases per 100 000. The
incidence reported from Israel is approximately
20-fold higher than that from the USA, which is
consistent with previous observations (11); the high
incidence in Israel is probably not representative of
most industrialized countries and reflects the high
endemicity of shigellosis in the Middle East (11).
These estimates do not take into account that
surveillance data are notoriously fraught with under-
reporting, the magnitude of which is uncertain (11,
57). By comparing the known number of Shigella cases
that occur during outbreaks with cases that actually
get reported to the health department during the
same outbreaks, the Centers for Disease Control and
Prevention (CDC) estimates that only 1–5% of
Shigella cases are reported, which suggests that the
cases ascertained by the health authorities under-
estimate the true incidence by a factor of 20–100 (57).
The incidences of shigellosis in the USA were
used to calculate the age-specific and total burden of
shigellosis in industrialized countries for the follow-
ing reasons: the data from the USA appear to be
representative of other industrialized countries; the
data are broken down by age; and a correction factor
for underreporting is available. To account for
underreporting, we multiplied the cases ascertained
by health authorities by a correction factor of 20,
yielding an overall incidence of 130 cases per 100 000.
If the total population living in developed countries is
Table 7. Age-specific annual incidence of shigellosis, by country, using cases reported to the national
surveillance systems of several industrialized countries
Annual number of cases per 100 000 population per year
Israelb
Age group USAa Jewish Non-Jewish England Australiad Francee
population population and Walesc
0–11 months 12.5 80 45 5.1 NRf NR
1–4 years 35.0 425 75 7.3 NR NR
5–14 years 13.0 200 25 8.3 NR NR
15–59 years 3.7 NR NR 6.3 NR NR
>60 years 1.1 NR NR 1.2 NR NR
Overall 6.5 130 3.3 5.6 1.8
a Data for 1 October 1994 to 12 September 1995 (ref. 55).
b Data for 1989–93 (ref. 56).
c 1996 data from the Public Health Laboratory Service, Communicable Disease Surveillance Centre, London, England.
d Population-based incidences comes from all States and Territories except New South Wales, where reporting was limited to foodborne or
institutional outbreaks.
e Surveillance based on cases reported to the Centre National de Re´fe´rence des Salmonella et Shigella, Institut Pasteur, Paris, from 1992 to 1997.
f NR: not reported.
Global burden of Shigella infections
657Bulletin of the World Health Organization, 1999, 77 (8)
1150 million, each year 1.5 million persons experi-
ence an episode of shigellosis.
Global burden of shigellosis. The total number
of Shigella episodes that occur each year through-
out the world is estimated to be 164.7 million, i.e.
163.2 million cases in developing countries and
1.5 million cases in industrialized countries (Table 8).
Mortality from shigellosis
in developing countries
Mortality in developing countries among infants
and 0–4-year-olds. An estimate of Shigella-associated
mortality among 0–4-year-olds can be derived using
the equations devised to calculate disease burden
(Tables 1–6). The results of this strategy are depicted
in Table 9. Mortality rates observed among patients
admitted to the inpatient unit of the International
Center for Diarrheal Diseases Research, Bangladesh
(ICDDR, B) over the period 1974–88 were used for
these calculations (6). Estimations indicate that
13.9% of infants and 9.4% of 1–4-year-olds who
are hospitalized with shigellosis die each year; the
total numbers of deaths in these age groups are
therefore 66 070 and 29 315, respectively (Table 9).
Studies performed in the 1980s in both rural
and urban settings have provided evidence that many
additional diarrhoeal deaths occur at home for
reasons that include family preference, access to
care, and long-term complications of the illness. A
one-year census-based survey of deaths among
children younger than 7 years in a rural area of the
Gambia found that only 12% of deaths occurred in a
hospital or health centre (58). Only 17.8% of deaths
detected during the 3 months following admission
for shigellosis to the rural Diarrhoea Treatment
Centre in Matlab, Bangladesh, occurred in the
treatment centre (6). The mortality rate among 2–5-
year-old children who had received medical treat-
ment for diarrhoea during the preceding 4 months
was slightly lower among those residing in urban
Bangladesh than in the Gambia; however, the
Bangladeshi study evaluated outpatients who were
presumably less severely ill (59). These studies
indicate that the true death rate may be 6–8-fold
higher than that indicated by hospital records (6, 58).
Multiplying the in-hospital mortality by a factor of
7 raises the death toll for infants to 462 490. A similar
calculation for 1–4-year-old children yields
205 205 deaths, making a total of 425 810 deaths
from Shigella infection among children aged 0–4 years
living in developing countries (Table 9).
Older children and adults. Each year approxi-
mately 6 744 075 episodes of shigellosis among older
children and adults living in developing countries are
evaluated in treatment centres (Table 5). It is estimated
that 11% of outpatients with Shigella infection are
admitted to a hospital, i.e. 741 850 cases (60). At the
ICDDR, B over the period 1974–88, 8.2% of patients
older than 5 years who were hospitalized with Shigella
infection died in the hospital (60), making 60 830
deaths each year for this age group. A correction for
out-of-hospital deaths, similar to that used for children
younger than 5 years of age, results in an estimated 425
810 Shigella deaths among older children and adults
living in developing countries (6, 58).
Total mortality from shigellosis among
persons residing in developing countries. Combining
the mortality calculated for all age groups, we
estimate the total Shigella-related mortality among
persons living in developing countries to be 1 093 505
(Table 9). In this estimate, children younger than




The death rate due to Shigella in developed countries is
exceedingly low. For example, the case-fatality rate
Table 8. Estimate of the global Shigella disease burden
No. of cases
Age group Developing Industrialized Total
(years) countries countriesa
0–4 113 163 260b 467 410 113 630 670
5–14 14 654 230c 408 875 15 063 105
15–59 30 065 470c 528 655 30 594 125
560 5 296 565c 46 915 5 343 480
Overall 163 179 525c 1 516 575 164 631 380
a Calculated by multiplying the population of industrialized countries falling into each age group
(ref. 35) by the age-specific incidence of shigellosis in the USA (Table 7) (ref. 55) and applying a
correction factor of 20 to compensate for underreporting (ref. 57).
b From Table 4.
c From Table 5.
Table 9. Estimated annual mortality from shigellosis in developing
countries, by age group
0–11 months 1–4 years 55 years
No. of hospitalized cases that
are infected with
Shigella spp.a 475 315 311 850 741 850b
No. of hospitalized shigellosis 66 070 29 315 60 830
cases that die (%) (13.9)c (9.4)c (8.2)d
No. of shigellosis cases
that die, corrected for
out-of-hospital mortalitye 462 490 205 205 425 810
Total Shigella deaths 1 093 505
a From Table 4.
b Each year approximately 6 744 075 episodes of shigellosis among older children and adults
living in developing countries are evaluated in treatment centres (Table 5), of whom an estimated
11% (741 850) are admitted to the hospital (ref. 60).
c From ref. 6.
d From ref. 60.
e Because many deaths occur at home, it has been suggested that the true death rate may be
7-fold higher than indicated by hospital records (ref. 6, 58).
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during the 1980s was reported to be 0.4% in the USA
(62) and 0.05% in Israel (56), with an average of 0.2%.
This means that approximately 3030 of the 1 516 575
cases of shigellosis that occur in industrialized
countries each year (Table 8) have a fatal outcome.
Shigellosis in high-risk populations
Although Shigella is endemic worldwide, it affects
certain populations more than others. In developing
countries, high rates of morbidity and mortality are
known to occur among displaced populations. Using
the USA as an example, identified risk groups in
industrialized countries include children in day-care
centres, native Americans on reservations, patients in
custodial institutions, and homosexual men, which
together account for approximately 13% of reported
isolates; international travellers and their household
contacts are responsible for an additional 20% (62).
Displaced populations. Sudden mass displace-
ment of people as a result of war, famine, and ethnic
persecution often results in large populations who
face insufficient supplies of clean water, poor
sanitation, overcrowding, and concomitant malnutri-
tion (63). In this setting, epidemics of dysentery have
caused high rates of morbidity and mortality among
all age groups in several populations recently,
including Bhutanese and Kurdish displaced popula-
tions in 1991 (64), Somalis in 1992 (63), Burundians
in 1993 (65), and Rwandans in 1994 (66– 68).
Dysentery produced extreme devastation among the
500 000–800 000 Rwandan refugees who fled into
the North Kivu region of Zaire in 1994. During the
first month alone, approximately 20 000 persons died
from dysentery caused by a strain of S. dysenteriae type
1 that was resistant to all of the commonly used
antibiotics (66).
Traveller’s diarrhoea. In 1995, roughly
116 million persons travelled from industrialized to
developing countries (personal communication, E.
Paci, World Tourism Organization, 1995). Diarrhoea
complicates approximately 50% of these trips (69),
resulting in 58 million cases of illness. Black et al.
reviewed all studies of traveller’s diarrhoea conducted
between 1974 and 1987 (69). In the 28 studies that
attempted to identify cases of shigellosis, the median
attack rate was 1% (range, 0–30%). If 50% of travellers
develop diarrhoea and 1% is due to Shigella, then there
are an estimated 580 000 cases of traveller’s shigellosis
among travellers from industrialized countries each
year.
Travellers are infected with multiresistant
Shigella with increasing frequency. In Helsinki,
Finland, between 1975 and 1988, the National
Shigella Reference Centre received 1951 Shigella
isolates collected from travellers (70). Whereas 3%
of strains were trimethoprim-resistant between 1975
and 1982, by 1988 a total of 98% were resistant. In the
USA, fewer than 5% of domestically acquired Shigella
isolates are resistant to trimethoprim–sulfamethox-
azole, while about 10% are resistant to ampicillin (62).
However, if there is a history of recent foreign travel
by the patient or by a household member with
diarrhoea, approximately 20% of isolates are resistant
to trimethoprim–sulfamethoxazole and 60% are
resistant to ampicillin (62).
Limited data on serotypes affecting travellers
are available. Among 235 strains isolated from
Japanese travellers, S. sonnei represented 64%,
S. flexneri 25%, S. boydii 8%, and S. dysenteriae 3%
(71). In national surveillance conducted in Finland
between 1985 and 1988, 175 Shigella isolates were
serotyped, yielding 71% S. sonnei, 25% S. flexneri, 3%
S. boydii, and <1% S. dysenteriae (70).
Shigella and the military. Throughout his-
tory, bacillary dysentery among soldiers has played a
decisive role in the course of military campaigns (72)
and the risk continues in modern deployments.
During Operation Desert Shield in the Arabian
peninsula, 57% of US troops experienced an episode
of diarrhoea and 20% reported that they were
temporarily unable to carry out their duties because
of diarrhoeal symptoms (73). Shigella was cultured
from 26% of episodes (or 15% of all troops), as
follows: S. sonnei (81%), S. flexneri (11%), S. boydii (7%),
and S. dysenteriae (4%). Most (85%) of the Shigella
strains tested were resistant to trimethoprim–
sulfamethoxazole. In the course of Operation
Restore Hope, during the famine and political unrest
in Somalia, Shigella was identified in 37 (33%) of
113 diarrhoeal stools that were cultured from US
soldiers: 23% were S. sonnei, 43% S. flexneri, 19% were
S. boydii, and 15% were S. dysenteriae (15). A high level
of resistance to doxycycline, ampicillin, and tri-
methoprim–sulfamethoxazole was reported.
Day-care centres. Shigellosis, particularly due
to S. sonnei, has been associated with young children in
schools and day-care centres from a number of
industrialized countries (13, 74–76). This places a
large proportion of young children at increased risk of
infection. For example, in 1995 approximately 48%
of the 65% of mothers in the USA who had children
under 6 years of age and who were employed enrolled
their children in family or centre-based day care (77).
Thus 12.9 million children under 6 years of age are in
day care with other children (78). It is well established
that children enrolled in group care have a higher risk
for shigellosis compared with age-matched controls
living at home (13, 79, 80). During a community-wide
outbreak of S. sonnei, children younger than 6 years
who attended day care were 2.4 times more likely to
experience shigellosis than were children who did not
(79). When outbreaks occur in the day-care setting,
attack rates are high (33–73%) (81) and secondary
cases may be detected in 26–33% of the families of
children who had Shigella-positive diarrhoea, con-
firming the important role of day-care centres in the
dissemination of Shigella infection to the community
(13, 82).
Sensitivity analysis
We conducted a sensitivity analysis for disease
burden and mortality. The best and worst case
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scenarios were substituted for events for which a
wide range of possible frequencies have been
published. Outliers were excluded from range
estimates, e.g. the percentage of Shigella diarrhoea
episodes that received medical attention in Teknaf,
Bangladesh, from Table 6 (46).
Burden of shigellosis. Ranges could be extra-
polated from published studies for the incidence of
diarrhoea in children from developing countries by
age (36) and for the proportion of episodes attributed
to Shigella (Tables 2, 3 and 6). Applying these ranges to
the sensitivity analysis suggests that the number of
episodes of shigellosis that occur each year in
developing areas of the world may be as low as
80.5 million, or as high as 415.6 million (Table 10).
For industrialized countries, we varied the assumed
proportion of cases that are reported to national
surveillance programmes from 10% (to derive a
minimum estimate) to 1% (a maximum estimate if a
correction factor of 100 were used, corresponding to
the upper limit proposed by Eichner et al. (57)). This
yielded a range of 750 000 to 7.5 million annual
episodes of Shigella infection in the industrialized
world. The worldwide burden is thus estimated to be
between 81.3 million and 415.6 million episodes each
year.
Mortality. Age-specific estimates of case fatal-
ity are sparse and most certainly vary widely,
reflecting regional rates of factors such as malnutri-
tion and access to medical care. For our estimates, we
used the median mortality rates by age for patients
infected with Shigella spp. who were admitted to the
inpatient unit of ICDDR, B in Bangladesh during
1974–88 (Table 9), since these data were based on a
prolonged observation interval, were systematically
collected, and included 2–3 years in which S. dysenter-
iae type 1 was epidemic (6). Since the appropriate
correction factor for out-of-hospital deaths is not
known, we arbitrarily varied it from 4- to 10-fold.
When these calculations were applied to the number
of persons hospitalized with shigellosis derived from
the sensitivity analysis, we estimated the annual death
toll to range from 768 790 to 11 635 920 persons.
Global distribution of Shigella serogroups
and serotypes
Distribution of serogroups. As shown in Fig. 1, the
majority (median 60%, range 25–86%) of Shigella
isolates from developing countries are S. flexneri, with
S. sonnei being the next most common (median 15%,
range 2–44%). S. dysenteriae (median 6%, range
1–31%) and S. boydii (median 6%, range 0–46%)
occur equally frequently. S. dysenteriae is seen most
often in South Asia and sub-Saharan Africa. In
contrast, data from Israel, Spain, and the USA
consistently demonstrate that S. sonnei is the most
common serogroup found in industrialized countries
(median 77%, range 74–89%), followed by S. flexneri
(median 16%, range 10–21%), S. boydii (median 2%,
range 2–5%) and finally S. dysenteriae (median 1%,
range 0–1%).
Distribution of serotypes. Among S. flexneri
isolates from developing countries (Fig. 2), serotype
2a causes 32–58% of infections, followed by serotype
1b (12–33%), 3a (4–11%), and finally 4a (2–5%) and
6 (3–5%). In the USA, S. flexneri 2a and other
Table 10. Sensitivity analysis of diarrhoeal disease burden and mortality in three settings in developing countries
Age group 0–11 months 1–4 years 5–14 years 15–59 years >60 years
Total population 125 000 000 450 000 000 1 011 000 000 2 647 000 000 330 000 000
Disease burden Low High Low High Low High Low High Low High
Diarrhoea episodes/person/year 2.7 5.0 1.7 3.0 0.65 0.65 0.5 0.5 0.69 0.69
Total diarrhoea (TD) episodes/year 337 500 000 625 000 000 765 000 000 1 350 000 000 657 140 250 657 140 000 1 323 304 000 1323 304 000 227 320 500 227 320 500
Diarrhoea episodes in domicile (DD)
No. of episodes (% of TD) 297 675 000 (88) 551 250 000 (88) 703 035 000 (92) 1240 650 000 (92) 643 997 450 (98) 643 997 450 (98) 1296 837 920 (98) 1296 837 920 (98) 222 774 090 (98) 222 774 090 (98)
No. with Shigella (% of DD) 5 954 000 (2) 27 563 000 (5) 42 182 100 (6) 235 723 500 (19) 6 439 970 (1) 19 319 920 (3) 12 968 380 (1) 38 905 140 (3) 2 227 740 (1) 6 683 220 (3)
Diarrhoea episodes in outpatients (OD)
No. of episodes (% of TD) 34 763 000 (10) 64 375 000 (10) 60 435 000 (8) 106 650 000 (8) 13 142 810 (2) 13 142 810 (2) 26 466 080 (2) 26 466 080 (2) 4 546 410 (2) 4 546 410 (2)
No. with Shigella (% of OD) 695 000 (2) 19 313 000 (30) 7 856 550 (13) 41 593 500 (39) 657 140 (5) 2 759 990 (21) 793 980 (3) 7 145 840 (27) 409 177 (9) 1 545 780 (34)
Diarrhoea episodes hospitalized (HD)
No. of episodes (% of TD) 5 063 000 (2) 9 375 000 (2) 1 530 000 (0.2) 2 700 000 (0.2)
No. with Shigella (% of HD) 203 000 (4) 1 031 000 (11) 122 400 (8) 864 000 (32)
No. of Shigella episodes:
Subtotal, by age strata 6 852 000 47 907 000 50 161 050 278 181 000 7 097 115 22 079 910 13 762 360 46 050 980 2 636 920 9 774 780
Subtotal, by age group Low: 57 012 300 High: 326 087 250 Low: 23 496 390 High: 89 488 332
Total annual Shigella episodes Low: 80 508 690 High: 415 575 580
Mortality Low High Low High Low High Low High Low High
Mortality from HD with Shigella:
Uncorrected (% of HD) 28 150 (14) 143 340 (14) 11 510 (9) 81 220 (9) 53 890 (8) 226 320 (8) 65 110 (8) 585 960 (8) 33 553 (8) 126 750 (8)
Corrected for out-of-hospital mortality 112 600 (4x) 1433 440 (10x) 46 020 (4x) 812 160 (10x) 215 540 (4x) 2 263 190 (10x) 260 430 (4x) 5 859 590 (10x) 134 210 (4x) 1267 540 (10x)
Subtotal, by age group Low: 158 610 High: 2 245 600 Low: 610 180 High: 9 390 320
Total annual Shigella deaths Low: 768 790 High: 11 635 920
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unspecified type 2 strains make up the largest
component of S. flexneri isolates, followed by
unspecified serotype 1 and 3. Among S. dysenteriae
isolates, type 1 predominates in India, Nigeria, and
Singapore (median for developing countries 30%,
range 0–67%), while type 2 predominates in
Guatemala, Hungary, and Yemen (median 23%,
range 0–70% of S. dysenteriae isolates). The third most
common serotype is type 3 (median 10%, range
0–20%). The remaining S. dysenteriae serotypes
identified in developing countries are 4, 5, 6, 7, 9
and 10. The S. dysenteriae isolates from the USA are
evenly distributed among types 1, 2 and 3. S. boydii
serotype 14 predominates in India, Nigeria, and
Yemen, where it accounts for 23–47% of isolates.
S. boydii type 1 predominates in Singapore (44%) and
serotype 2 in Guatemala (40%). In the USA, serotype
2 accounts for the largest proportion (42%) of S. boydii
isolates.
Discussion
Diarrhoeal disease continues to be a leading cause of
morbidity and mortality worldwide, and is ranked
fourth as a cause of death (83) and second as a cause
of years of productive life lost due to premature
mortality and disability (84). Even though economic
development and progress in health care delivery are
expected to catalyse substantial improvements in
infectious-disease-related morbidity and mortality
during the next 30 years, it is predicted that diarrhoea
will remain a leading health problem (85). There has
been increased recognition in recent years of the
importance of Shigella as an enteric pathogen with
global impact, and of the potentially devastating
consequences if resistant strains outpace the avail-
ability of affordable and effective antimicrobial
therapy. This awareness has led Shigella to be targeted
by WHO as one of the enteric infections for which
new vaccines are most needed and has prompted the
present review, which estimates the global burden of
Shigella disease.
We have estimated that each year 163.2 million
episodes of endemic shigellosis occur in developing
countries (3.5% of the population) and 1.5 million in
industrialized countries (0.1% of the population).
Approximately 1.1 million episodes (0.7%) result in
death. Under-5-year-olds comprise the majority of
cases (69%) and of fatal outcomes (61%). While
death from Shigella infection is a rare outcome in
industrialized countries, morbidity can be substantial
when outbreaks of shigellosis occur in custodial
institutions and day-care centres, and when shigello-
sis occurs among soldiers and travellers. It is
interesting to compare our findings with other
attempts to quantify the diarrhoeal disease burden.
In 1984, an expert panel assembled by the Institute of
Medicine estimated, on the basis of published studies
and field experience, that the annual number of
Shigella episodes in developing countries was 251 mil-
lion, with 654 000 deaths. Extrapolation of these
rates to the 1994 global population estimates would
yield 324 million cases and 843 000 deaths (54), which
is remarkably similar to our figures, considering the
number of potential sources of error involved. Our
findings can also be viewed in the context of an
analysis performed by Bern et al. of the burden of
diarrhoeal disease among young children living in
developing countries. Based on published studies,
Bern et al. estimated that, in 1990, children aged
<5 years experienced approximately 1000 million
episodes of diarrhoea per year, resulting in 3.3 million
deaths (range 1.5–5.1 million) (36). Our findings,
which are based in part on the incidence of diarrhoea
among under-5-year-olds reported by Bern et al., are
consistent with these estimates if Shigella causes
5–10% of diarrhoeal illnesses and 75% of diarrhoeal
death (6).
It is difficult to derive a credible estimate of
disease burden by compiling studies which vary in
place, time, socioeconomic conditions, and study
design, even if criteria for data inclusion are stringent.
Nevertheless, there are many reasons to suspect that
the potential sources of error have resulted in
conservative estimates of disease burden. First,
Shigella is a fastidious organism to cultivate under
most field conditions, where prompt processing of
fresh faecal material is not always possible; this would
Fig 1. Percentage of Shigella isolates belonging to four sero-
groups, by region. A median percentage was calculated for each region.
When multiple studies were performed in one country, a median for each
country was first calculated. The countries represented in each region were:
South Asia (Bangladesh (5,44) and India (104)); East Asia and Pacific
(Thailand (101, 105, 106), Malaysia (114) and Singapore (107)); sub-
Saharan Africa (Nigeria (43, 108)); Middle East (Kuwait (109), Saudi Arabia
(110, 111), Turkey (112) and Yemen (113)); Latin America (Chile (32) and
Guatemala (34)); and industrialized countries (Spain (115), Israel (116–118)
and USA (55)).
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falsely lower estimates of the proportion of diarrhoeal
cases attributable to it. Second, the hospitalization
rates for children aged <5 years (1.5% of diarrhoeal
episodes) used in our calculations as a surrogate for
severe disease may be low for developing countries
because they were derived from surveillance con-
ducted in Chile, a rapidly developing country with a
strong health care infrastructure, little malnutrition,
and almost no S. dysenteriae type 1 infections. In
contrast, 10% of patients arriving with diarrhoea at
the Diarrhoea Treatment Centre in Dhaka, Bangla-
desh, are admitted to a unit for inpatients (6). Third, it
is likely that we have underestimated the incidence of
diarrhoea among older children and adults living in
developing countries (for whom the data are sparse);
higher rates of diarrhoea and enteric illness have been
reported among similarly aged populations living in
the USA during the 1950s to 1970s (86, 87).
Furthermore, population-based studies in the USA
indicate that a physician is consulted for 15% of
episodes of diarrhoeal illness (86), whereas we
estimated that only 2% of older children and adults
from developing countries seek medical care. Fourth,
although the use of inpatient case-fatality rates
derived from Dhaka (a highly underserved popula-
tion) may produce overestimates of case fatality, our
calculations did not fully account for the sudden
excess of cases and deaths that occurs when epidemic
waves of Shiga dysentery strike a region. This
devastating form of shigellosis is associated with
high rates of illness (attack rates have ranged from
1.2% in El Salvador to 32.9% during an outbreak on
St Martin island) and case fatality (ranging from 0.6%
during an epidemic in Myanmar (Burma) to 7.4% in
the Guatemalan epidemic) (6, 8 ,9, 68, 88, 89). Finally,
the available data only permit an estimation of deaths
that occur during the acute or subacute phase of
shigellosis. Deaths that result after extended periods
of persistent diarrhoea, intestinal protein loss, and
chronic malnutrition following shigellosis could not
be measured.
A safe and effective Shigella vaccine offers great
potential as a means of controlling shigellosis. The
ability of Shigella antigens to confer a high degree of
serotype-specific immunity has been observed in
several situations, e.g. large-scale field trials with the
streptomycin-dependent vaccines of Mel et al. (90,
91), studies of volunteers who were inoculated with
either the vaccine or wild-type Shigella and then
challenged with the homologous virulent serotype
(92– 94), and natural history studies in Chile (32).
However, protection across the four species
(S. dysenteriae, S. flexneri, S. boydii, and S. sonnei, also
designated as groups A, B, C and D, respectively)
does not occur (95).
Strategies for vaccine development must take
into consideration the 47 antigenically distinct
serotypes of Shigella. Groups A, B, and C contain
multiple serotypes (13, 6 (15 including subtypes), and
18, respectively), whereas group D contains only a
single serotype. Our analysis highlights the Shigella
strains that are most critical and which should be
included in a potential vaccine. S. sonnei is an essential
vaccine component since it is responsible for 15% of
infections in developing countries and 77% in
industrialized countries. S. dysenteriae comprises only
a small proportion of the overall burden from
endemic disease (median, 6% in developing countries
and 1% in industrialized countries). However, the
severe manifestations characteristic of serotype 1,
which comprised about 30% of S. dysenteriae isolates,
and its ability to cause pandemic spread, harbour
multiple antibiotic resistances, and produce high
attack rates and case fatality in all age groups, argue
for its inclusion in a polyvalent formulation. The
presence of 15 serotypes of S. flexneri presents a
logistic barrier for vaccine development. There is
evidence of serologic cross-reactivity in humans (96)
and of cross-protection among the S. flexneri
serotypes in animals (97), suggesting that broad
S. flexneri protection may be feasible with the use of
innovative strategies. If a polyvalent vaccine cocktail
could be developed that covers 100% of S. flexneri
strains, the addition of S. sonnei and S. dysenteriae type 1
could provide protection against an estimated 79% of
Shigella infections in developing countries and 83% in
industrialized countries. If this vaccine had 70%
efficacy and the coverage was high, up to 91 million
infections (90.2 million in developing countries and
881 130 in industrialized countries) and 605 000
deaths might be prevented each year. n
Fig. 2. Distribution of Shigella flexneri serotypes isolated in the
following countries: Malaysia (114), Philippines (103), Yemen (113),
Singapore (107), Hungary (119), Chile (32), and USA (55). Only serotypes
that constitute more than 1% of total S. flexneri isolates are shown.
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Re´sume´
Charge de morbidite´ des infections a` Shigella dans le monde : incidence sur la mise au
point et l’utilisation des vaccins
Peu de publications fournissent les donne´es ne´cessaires
pour pouvoir estimer la morbidite´ et la mortalite´
associe´es aux infections a` Shigella dans le monde. De
telles estimations sont pourtant importantes, puisqu’on
en a besoin pour planifier les programmes de mise au
point et d’utilisation des vaccins et autres strate´gies de
lutte.
Nous avons passe´ en revue la litte´rature scienti-
fique publie´e entre 1966 et 1997 afin d’obtenir des
donne´es permettant de calculer le nombre de cas
d’infections a` Shigella et la mortalite´ qui leur est associe´e
chaque anne´e dans le monde. La charge de morbidite´ a
e´te´ de´termine´e se´pare´ment pour les pays en de´veloppe-
ment et les pays industrialise´s, par groupe d’aˆge
(0–11 mois, 1–4 ans, 5–14 ans, 15–59 ans et
560 ans) et, a` titre d’indicateur de gravite´ de la
maladie, par cate´gorie clinique (cas be´nins soigne´s a`
domicile, cas plus graves ayant ne´cessite´ des soins
cliniques dans un centre de traitement mais sans
hospitalisation, et cas ayant ne´cessite´ une hospitalisa-
tion). On a effectue´ une analyse de sensibilite´ pour
pouvoir estimer les valeurs supe´rieures et infe´rieures de
la morbidite´ et de la mortalite´ dans chaque cate´gorie.
Enfin, on a de´termine´ la distribution de fre´quence des
infections a` Shigella par se´rogroupe et par se´rotype pour
les diffe´rentes re´gions du monde.
Le nombre annuel d’e´pisodes de diarrhe´e a`
Shigella se produisant dans le monde a e´te´ estime´ a`
164,7 millions, dont 163,2 millions dans les pays en
de´veloppement (fourchette 80,5–415,6 millions) et
1,5 million dans les pays industrialise´s (fourchette 0,8–
7,5 millions). On estime a` 1,3 million (fourchette 0,3–
4,9 millions) la mortalite´ totale associe´e aux infections a`
Shigella chez les personnes vivant dans les pays en
de´veloppement. Dans ces estimations, les enfants de
moins de 5 ans repre´sentent 69% de tous les e´pisodes et
61% de tous les de´ce`s imputables a` la shigellose. Les
pourcentages me´dians des isolements de Shigella ont e´te´
les suivants : S. flexneri (60%), S. sonnei (15%),
S. boydii (6%) et S. dysenteriae (6% : dont 30% sont
des isolements de S. dysenteriae type 1) dans les pays en
de´veloppement; et elle a e´te´ respectivement de 16%,
77%, 2% et 1% dans les pays industrialise´s. Dans les
pays en de´veloppement, les se´rotypes de S. flexneri qui
pre´dominent sont le 2a (32–58%), suivi du 1b (12–
33%), du 3a (4–11%), et enfin du 4a (2–5%) et du 6 (3–
5%). Dans les pays industrialise´s, la plupart des
isolements appartiennent au se´rotype 2a de S. flexneri
ou a` d’autres souches de type 2 non spe´cifie´es. Les
shigelles jouent re´gulie`rement un roˆle important comme
germes ente´ropathoge`nes ayant un impact mondial, que
les mesures de pre´vention et de traitement existantes ne
permettent pas de maıˆtriser suffisamment. Des strate´gies
novatrices visant a` mettre au point un vaccin permettant
de couvrir les se´rotypes les plus re´pandus pourraient
offrir bien des avantages.
Resumen
Carga mundial de infecciones por Shigella : implicaciones para el desarrollo y empleo de
vacunas
Pocas son las publicaciones que facilitan los datos
necesarios para estimar la morbilidad y mortalidad
mundiales asociadas a las infecciones por Shigella. Sin
embargo, esas estimaciones son importantes, dada su
necesidad para establecer programas de desarrollo y
empleo de vacunas y otras estrategias de control.
Examinamos la literatura cientı´fica publicada entre
1966 y 1997 para obtener datos a fin de calcular el
nu´mero de casos de Shigella que se producen cada an˜o
en todo el mundo y la consiguiente mortalidad. Se
determino´, por separado, la carga de la enfermedad para
los paı´ses en desarrollo y para los industrializados, por
estratos de edad (0-11 meses, 1-4 an˜os, 5-14 an˜os, 15-
59 an˜os y560 an˜os) y, como indicador de la gravedad
de la enfermedad, por categorı´as clı´nicas (casos leves
que permanecen en casa, casos ma´s graves que
necesitan atencio´n clı´nica en un centro de tratamiento
pero que no requieren hospitalizacio´n, y casos que
exigen hospitalizacio´n). Se realizo´ un ana´lisis de
sensibilidad para estimar los valores ma´ximo y mı´nimo
de la morbilidad y la mortalidad en cada categorı´a.
Finalmente, se determino´ la distribucio´n de frecuencias
de la infeccio´n por Shigella por serogrupo y serotipo y por
regio´n del mundo.
El nu´mero anual de episodios de infeccio´n por
Shigella que se producen en todo el mundo se estima en
164,7 millones, que incluyen 163,2 millones de casos en
los paı´ses en desarrollo (intervalo 80,5-415,6 millones) y
1,5 millones de casos en los paı´ses industrializados
(intervalo 0,8-7,5 millones). La mortalidad total asociada
a Shigella entre las personas que habitan en los paı´ses en
desarrollo se estima en 1,3 millones (intervalo 0,3-4,9
millones). En estas estimaciones, los nin˜os menores de
cinco an˜os representan el 69% de todos los episodios y el
61% de todas las defunciones atribuibles a shigelosis. La
proporcio´n mediana de aislamientos de Shigella fue la
siguiente: S. flexneri (60%), S. sonnei (15%), S. boydii
(6%) y S. dysenteriae (6%: un 30% de los cuales
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corresponden a S. dysenteriae tipo 1) en los paı´ses en
desarrollo; y 16%, 77%, 2% y 1% respectivamente en
los paı´ses industrializados. En los paı´ses en desarrollo los
serotipos de S. flexneri predominantes son 2a (32%-
58%), seguido de 1b (12%-33%), 3a (4%-11%) y, por
u´ltimo, 4a (2%-5%) y 6 (3%-5%). En los paı´ses
industrializados la mayorı´a de los aislamientos corres-
ponden a S. flexneri 2a o a otras cepas del tipo 2 no
especificadas. Shigella tiene grandes repercusiones
como pato´geno ente´rico a nivel mundial, y no puede
controlarse correctamente con las medidas de preven-
cio´n y tratamiento existentes. La aplicacio´n de estrate-
gias innovadoras con miras al desarrollo de una vacuna
que abarque los serotipos ma´s comunes podrı´a aportar
beneficios sustanciales.
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